Biotechnology - Techseriesinsight

December 6, 2024
PRNewswire
Biotechnology

Another star technology platform of the Sanyou AI-STAL family

With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes...

December 6, 2024
Business Wire
Biotechnology

Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery

Alithea Genomics, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS™ Full-Length DRUG-seq library preparation technology, which combines, for the first...

December 5, 2024
PRNewswire
Biotechnology

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eckert & Ziegler, one of the world’s largest providers...

December 5, 2024
Business Wire
Biotechnology

FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License...

December 4, 2024
Business Wire
Biotechnology

ESYA Labs Partners with Alamar Biosciences to Advance Biomarker Detection and Diagnostics for Neurological Diseases

ESYA Labs, a global leader in lysosomal biology and biomarker discovery for neurodegenerative diseases, has announced a transformative partnership with Alamar Biosciences, a pioneer in ultra-sensitive immunoassay technologies. By...

December 2, 2024
PRNewswire
Biotechnology

Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan

Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. (“Travere”) and currently in phase III clinical trials in Japan, has received Orphan Drug...

November 28, 2024
Business Wire
Biotechnology

Dr. Reddy’s launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), announced the launch of Toripalimab in India....

November 28, 2024
PRNewswire
Biotechnology

Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced that the company has entered into an exclusive licensing agreement with Medvisis Switzerland AG (“Medvisis”) in Switzerland and Liechtenstein, for exclusive rights to the commercialization of...

November 28, 2024
PRNewswire
Biotechnology

New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication...

November 28, 2024
PRNewswire
Biotechnology

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China’s National Reimbursement Drug List

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and...